• 목록
• 답변

Arbormed announced on the 25th that it has released the therapeutic potential of a study on "ARBM-201, a candidate for the treatment of Acute Respiratory Distress Syndrome (ARDS), for the first time at the "2022 American Thoracic Society (ATS 2022)" held in San Francisco from the 13th to the 18th (local time).

Pendrin protein is a protein that exchanges ions in various types of cells in the body, and is present in the inner ear, thyroid, and airway epithelial cells, and is known to increase pendrin's expression in patients with asthma, chronic obstructive diseases, and allergic rhinitis. ARBM-201, a pendrin inhibitor Arbormed is being developed as a first-in-class that reduces the inflow of thiocyanate and hypothiocyanite ions into the alveolar lumen to inhibit lung damage due to inhibition of protein NF-kB involved in inflammatory reactions and reduction of inflammatory cytokines.

The presentation, which was conducted as a poster session, includes the results of the pendrin inhibitory function and efficacy evaluation of ARBM-201, which is based on experiments in cell and animal models.

According to the results of in-vitro experiments, ARBM-201 showed a significantly low "IC50" value of 0.9μM, which sees the drug concentration required to reduce the inhibition of anion exchange to half. In addition, it was confirmed that pendrin overexpressed due to LPS in human alveolar epithelial cells was suppressed after ARBM-201 treatment.

As a result of observing efficacy in animal models that induced infection with LPS, when intravenously administered twice a day with ARBM-2011ug/kg, phenrine protein expression was suppressed to a normal level, and the total number of cells and protein amount of bronchial alveolar lavage (BALF) was significantly reduced. In addition, the inflammatory cytokines IL-1 M, MIP-2, IL-6, and TNF-α were all significantly reduced, and the damage score and inflammatory indicators were significantly improved as a result of histopathological tests in lung tissue.

Currently, there is no effective treatment for acute respiratory distress syndrome, and furthermore, steroids administered to patients in intensive care units are known to have very large side effects compared to insignificant effects. In addition, clinical trials of drug repositioning and new drug development that regulate specific immune responses or block inflammatory pathways are underway, but the therapeutic effect has not been verified.

"Pendrin is expected to be more effective than drugs that suppress specific inflammatory targets, as it can control all kinds of inflammatory cytokines at the top of the inflammatory pathway," said co-CEO Arbormed Im Weonbin. "ARBM-201, which is currently in the nonclinical stage and aims to submit to Korea or the U.S. within the next two years.